Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;101(11):2549-2550.
doi: 10.1007/s00277-022-04939-z. Epub 2022 Aug 4.

Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?

Anne Boerekamps  1 , Paul Hamberg  2 , Eduard J Libourel  2
Affiliations

Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?

Anne Boerekamps et al. Ann Hematol. 2022 Nov.
No abstract available

PubMed Disclaimer

References

    1. Sekeres MA et al (2020) American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv 4(15):3528–3549 - DOI
    1. Dohner H et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447 - DOI
    1. Fenaux P et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562–569 - DOI
    1. Dombret H et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126(3):291–299 - DOI
    1. Kantarjian HM et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670–2677 - DOI

MeSH terms

Substances

LinkOut - more resources